Novartis AG
151.12USD
-5.1500 (-3.30%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on NVS.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 43.5B | 46.7B | 51.7B | 56.7B | 57.5B | 61.4B |
| Q1 | — | — | — | — | 13.5B | — |
| Q2 | — | — | — | 14.8B | 15.0B | — |
| Q3 | — | — | — | 14.4B | 14.6B | — |
| Q4 | — | — | — | 13.9B | 15.0B | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 3.17 | 7.10 | 5.87 | 7.15 | 8.83 | 9.80 |
| Q1 | — | — | — | — | 1.65 | — |
| Q2 | — | — | — | 2.06 | 1.71 | — |
| Q3 | — | — | — | 2.02 | 2.24 | — |
| Q4 | — | — |
Fiscal period: Reported, Estimated. Reported figures: Yahoo Finance (limited history). Estimates are sell-side consensus for periods that have not reported. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| — |
| 1.25 |
| 2.22 |
| — |
Debt level and coverage